[{"id":"49a4a0b5-0da7-4007-b016-2998d04ed0a0","acronym":"REFLECT","url":"https://clinicaltrials.gov/study/NCT04031898","created_at":"2021-01-18T19:47:14.893Z","updated_at":"2024-07-02T16:36:36.923Z","phase":"","brief_title":"Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)","source_id_and_acronym":"NCT04031898 - REFLECT","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ALK • TP53 • MET","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • HER-2 amplification • EGFR exon 19 deletion • MET amplification • EGFR T790M • MET expression • ALK rearrangement + MET amplification • HER-2 exon 23 mutation","tags":["HER-2 • ALK • TP53 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • HER-2 amplification • EGFR exon 19 deletion • MET amplification • EGFR T790M • MET expression • ALK rearrangement + MET amplification • HER-2 exon 23 mutation"],"overall_status":"Completed","enrollment":" Enrollment 896","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2020-12-23"}]